NEW ANGICOR

Angicor® is Apixaban, a potent, reversible, direct, and highly selective inhibitor of coagulation factor Xa.

It does not require antithrombin III for its antithrombotic activity.

Apixaban inhibits both free factor Xa and clot-bound factor Xa, as well as prothrombinase activity. Angicor® contains Apixaban of 2.5 mg and 5 mg.

Approval indications:

• Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.
• Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors such as previous stroke or transient ischemic attack (TIA); age = 75 years; hypertension; diabetes mellitus; symptomatic heart failure (= Class 2 NYHA scale).
• Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrence of DVT and PE in adult patients.

Angicor, Apixaban 2.5 mg and 5 mg, presentations in a box containing 30 and 60 film-coated tablets.